As of Nov 19, 2026, 2 of 2 active firms rate VRCA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VRCA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.44
Range $-0.57 – $-0.33 · 3 analysts
Next period, 3 analysts expect Verrica Pharmaceuticals Inc to earn $-0.44 a share (range $-0.57 – $-0.33), versus — a year earlier. Full-year consensus is $-1.89, growing to $-1.36 the year after.
REVENUE · NEXT QUARTER
$7.2M
Range $5.9M – $8.4M · 3 analysts
Revenue is expected to reach $7.2M (range $5.9M – $8.4M). Full-year consensus is $24.7M, rising to $38.2M next year.
Top analysts covering Verrica Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRCA.
#1
Serge Belanger
Needham · Rank #129
Neutral
No targeton VRCA
Overall win rate
46%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #217
Neutral
No targeton VRCA
Overall win rate
54%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$12.00+313.8% to target
Overall win rate
36%
+ Follow
#4
KD
Kemp Dolliver
Brookline Capital Markets
Buy
$17.00+486.2% to target
Coverage
—
+ Follow
#5
DP
Dev Prasad
Lucid Capital
Buy
$19.00+555.2% to target
Coverage
—
+ Follow
VRCA stock forecast FAQ
What is VRCA's average 12-month price target?+
The 2 active firms with a live target average $14.50 for Verrica Pharmaceuticals Inc over the next 12 months, ranging from a $17.00 high to a $12.00 low, as of Nov 19, 2026.
Is VRCA stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VRCA?+
The Street-high target is $17.00 (Brookline Capital), and the Street-low is $12.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $14.50.
How many active Wall Street firms cover VRCA?+
2 active firms have a recognized rating on Verrica Pharmaceuticals Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VRCA?+
Among analysts who currently cover VRCA, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #129). Their current call is Neutral.
What is Verrica Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.44 per share (range $-0.57 – $-0.33) across 3 analysts. Full-year EPS is projected at $-1.89, rising to $-1.36 the following year.
How much revenue is Verrica Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $7.2M (range $5.9M – $8.4M). Full-year revenue is projected at $24.7M, growing to $38.2M next year.
Have analysts been upgrading or downgrading VRCA lately?+
As of Nov 19, 2026, 2 of 2 active firms rate VRCA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRCA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.